TABLE I.
Baseline Demographics and Characteristics (FSA Population)*
| Prior Bisphosphonate Treatment |
|||
| Variable | All Subjects, N = 34 | Yes, N = 21 | No, N = 13 |
| Age† (yr) | 62 ± 8 | 61 ± 8 | 63 ± 9 |
| Origin‡ | |||
| White | 31 (91) | 19 (90) | 12 (92) |
| Hispanic or West Asian | 3 (9) | 2 (10) | 1 (8) |
| Time since menopause† (yr) | 17 ± 12 | 16 ± 9 | 18 ± 16 |
| Prevalent fracture‡ | |||
| Any vertebral fracture | 4 (12) | 1 (5) | 3 (23) |
| Any nonvertebral fracture | 17 (50) | 11 (52) | 6 (46) |
| Areal BMD T-score† | |||
| Lumbar spine | −2.9 ± 1.0 (n = 30) | −2.8 ± 1.2 (n = 18) | −3.1 ± 0.8 (n = 12) |
| Femoral neck | −2.4 ± 0.7 (n = 34) | −2.5 ± 0.7 (n = 21) | −2.2 ± 0.7 (n = 13) |
| Total hip | −1.8 ± 0.8 (n = 34) | −1.8 ± 0.9 (n = 21) | −1.7 ± 0.7 (n = 13) |
| Areal BMD† (g/cm2) | |||
| 1/3 distal radius | 0.6 ± 0.9 (n = 34) | 0.6 ± 0.1 (n = 21) | 0.6 ± 0.1 (n = 13) |
| Ultra-distal radius | 0.3 ± 0.1 (n = 34) | 0.3 ± 0.1 (n = 21) | 0.3 ± 0.1 (n = 13) |
| Volumetric BMD† (mg/cm3) | |||
| Spine | 145.9 ± 19.55 (n = 30) | 149.2 ± 21.17 (n = 19) | 140.3 ± 15.7 (n = 11) |
| Hip | 207.6 ± 27.91 (n = 27) | 208.7 ± 27.36 (n = 17) | 205.9 ± 30.24 (n = 10) |
| Total lumbar spine strength† (N) | 4236 ± 888.09 (n = 30) | 4428.47 ± 1001.87 (n = 19) | 3904.73 ± 537.98 (n = 11) |
| Total hip strength† (N) | 2786.48 ± 520.46 (n = 27) | 2728.24 ± 550.96 (n = 17) | 2885.50 ± 474.96 (n = 10) |
| P1NP† (μg/L) | 42.8 ± 20.3 (n = 33) | 38.2 ± 18.7 (n = 21) | 50.8 ± 21.1 (n = 12) |
| CTX† (ng/mL) | 0.6 ± 0.3 (n = 33) | 0.6 ± 0.3 (n = 21) | 0.7 ± 0.2 (n = 12) |
*
FSA = full-set analysis, CTX = serum carboxyterminal cross-linking telopeptide of collagen type 1, and P1NP = serum procollagen type 1 N-terminal propeptide.
†
The values are given as the mean and standard deviation, with the number of subjects with data in parentheses.
‡
The values are given as the number of subjects, with the percentage in parentheses.